StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project：[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
Zurück
HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 5281069Erstellt: 29. Oktober 2026

[R-(R*,R*)]-2-[2-[1-(p-Chlorphenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidiniumhydrogenfumarat

hs592 · tavist · Alagyl · agasten · lecasol · piloral · reconin · tavegil

https://huagongshe.com/de/chemical/5281069

Molekülstruktur von [R-(R*,R*)]-2-[2-[1-(p-Chlorphenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidiniumhydrogenfumarat

Identifikatoren & physikalische Daten

CAS No.14976-57-9
SummenformelC25H30ClNO5
Durchschnittliche Molmasse460 g/mol
Monoisotopische Masse459,1812508 g/mol
SMILESCN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1.O=C(O)/C=C/C(=O)O
InChIKeyPMGQWSIVQFOFOQ-YKVZVUFRSA-N
PubChem CID5281069
ChEMBLCHEMBL1200795
ChEBICHEBI:3739
EC No.239-055-2
DTXSIDDTXSID6047785
Lokaler Name[R-(R*,R*)]-2-[2-[1-(p-Chlorphenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidiniumhydrogenfumarat

Chemische & physikalische Eigenschaften

Polarare Oberfläche (TPSA)87,1
H-Brücken-Donoren2
H-Brücken-Akzeptoren6
Frei drehbare Bindungen8
Schwere Atome32
Formalladung0
Komplexität495
GeruchOdorless
Color/FormColorless to faintly yellow crystalline powder
LöslichkeitVery slightly soluble in water and sparingly soluble in alcohol.DMSO: soluble5mg/mL (clear solutionwarmed)
Human DrugsFDA approved drugs -> Active ingredient
Siedepunkt154 °C at 0.02 mm Hg154°C (rough estimate)
Schmelzpunkt177-178 °C158-162°C
Other Experimental Properties154 °C at 0.02 mm Hg (free base)
Dichte1.0247 (rough estimate)
Brechungsindex1.5790 (estimate)
Lagerbedingungen2-8°C
Aggregatzustandpowder
Farbewhite to beige
InChIKeyPMGQWSIVQFOFOQ-YKVZVUFRSA-N
SMILES[C@@](C)(OCC[C@H]1CCCN1C)(C1C=CC=CC=1)C1=CC=C(Cl)C=C1.C(/C(=O)O)=C\C(=O)O |&1:0,5,r|
CAS Datenbank14976-57-9(CAS DataBase Reference)

Sicherheit & Vorschriften

GHS-EinstufungThis chemical does not meet GHS hazard criteria for 66.7% (12 of 18) of all reports.WarningH400 (22.2%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]P273, P391, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 18 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
FDA-AnforderungenManufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392).The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed drug products, incl clemastine fumarate, approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. /From the Prescription Drug Product List/
Hazard Classes and CategoriesAquatic Acute 1 (22.2%)
KörperbelastungFollowing oral administration of 2.68 mg of clemastine fumarate daily for 3 days in one nursing woman, a milk clemastine concentration of about 5-10 ug/ml occurred 20 hours after the last dose of the drug.
Milk ConcentrationsFollowing oral administration of 2.68 mg of clemastine fumarate daily for 3 days in one nursing woman, a milk clemastine concentration of about 5-10 ug/ml occurred 20 hours after the last dose of the drug.
Human Toxicity ExcerptsUsual therapeutic doses of clemastine interfere with color vision.Drowsiness, irritability, refusal to feed, and high-pitched cry occurred in one breast-fed infant (10 weeks of age) of a women who received 2.68 mg of clemastine fumarate daily for 3 days.
Drug Induced Liver InjuryDrug Induced Liver Injury Rank (DILIrank 2.0)Clemastine fumaratevNo-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015

Anwendungen & Verwendung

Verwenden

Clemastine fumarate is a selective histamine H1 receptor antagonist (Ki = 0.26 nM) that also displays high affinity for muscarinic receptors (Ki = 16 nM). It has also recently been identified as a positive allosteric modulator of P2X7 receptor signaling. Clemastine fumarate has long been used to inhibit histamine-induced bronchoconstriction in asthma and airway hyperresponsive studies.

Non-Human Toxicity ExcerptsReproduction studies in rats and rabbits using oral clemastine fumarate dosages up to 312 and 188 times the usual human adult dosage, respectively, have not revealed evidence of harm to the fetus. Reproduction studies in rats and rabbits using oral clemastine fumarate and phenylpropanolamine hydrochloride in a fixed combination ratio of 1:49 and at oral dosages up to 100 (in rats) and 67 (in rabbits) times the usual human dosage have not revealed evidence of teratogenic effects. Impaired maternal weight gain and death at 33 times the usual human dosage, and reduced fetal weight and slight increases in preimplantation loss and prenatal death at 100 times the usual human dosage were attributed to phenylpropanolamine in rats. Increased maternal death at dosages 20 and 67 times the usual human dosage, and maternal weight loss and a slight (but within normal limits) increase in prenatal death at a dosage 67 times the usual human dosage were attributed to phenylpropanolamine in rabbits.Oral dosage of clemastine fumarate 312 times the usual human adult dosage have decreased mating ability in male rats, but dosages 156 times the usual human adult dosage had no effect on mating.There was no evidence of carcinogenesis in rats receiving clemastine fumarate at an oral dosage of 84 mg/kg (about 500 times the usual human adult dosage) for 2 years or in mice receiving 206 mg/kg (about 1300 times the usual human adult dosage) for 85 weeks. The carcinogenic potential of clemastine fumarate in fixed combination with phenylpropanolamine has not been determined.
Antidote and Emergency TreatmentSince there is no specific antidote for overdose with antihistamines, treatment is symptomatic and supportive with possible utilization of the following: 1) Induction of emesis (syrup of ipecac recommended)however, precaution against aspiration necessary, especially in infants and children. 2) Gastric lavage (isotonic or 0.45% sodium chloride solution) if patient unable to vomit within three hours of ingestion. 3) Saline cathartics (milk of magnesia) are sometimes used. 4) Vasopressors to treat hypotensionhowever, epinephrine should not be used since it may further lower blood pressure. 5) Oxygen and intravenous fluids. 6) Precaution against use of stimulants (analeptic agents) because they may cause seizures. /Antihistamines/
Non-Human Toxicity ValuesLD50 Mouse oral 730 mg/kgLD50 Mouse iv 43 mg/kgLD50 Rat oral 3550 mg/kgLD50 Rat iv 82 mg/kg
Wassergefährdungsklasse (WGK)3
Zollcode2933992600
RTECS-Nr.UY0704600
ToxizitätLD50 in mice, rats (mg/kg): 730, 3550 orally43, 82 i.v. (Weimann)
Lagerklasse11 - Combustible Solids
Gefahrstoffdaten14976-57-9(Hazardous Substances Data)